Mir-484在妇科肿瘤诊疗中的研究进展

Research Advances on Mir-484 in Gynecologic Malignancy Diagnosis and Treatment

摘要: 越来越多的证据表明，微小RNA (miRNA)作为多种生物学过程的关键调控因子，其表达异常与肿瘤的发生、发展、增殖及化疗耐药性密切相关。miR-484作为其中具有重要研究价值的成员，其编码基因定位于染色体16p13，已被证实在宫颈癌、卵巢癌、子宫内膜癌等多种妇科肿瘤及其他恶性肿瘤中存在表达异常，且与肿瘤的临床病理特征及患者预后紧密相关。其中，外泌体包裹的miR-484在体液中稳定性更高，是极具潜力的循环生物标志物。本文系统综述了miR-484在宫颈癌、子宫内膜癌、卵巢癌中的表达特征、靶向调控机制，及其在疾病诊断、预后评估和化疗耐药逆转中的作用与应用价值，旨在为miR-484在妇科肿瘤临床诊疗中的转化应用提供理论参考。

Abstract: A growing body of evidence indicates that microRNAs (miRNAs), as key regulators of various biological processes, have abnormal expression closely associated with the occurrence, development, proliferation, and chemoresistance of tumors. As a member with significant research value, miR-484 is encoded by a gene located on chromosome 16p13. It has been confirmed to be abnormally expressed in various gynecologic malignancies such as cervical cancer, ovarian cancer, and endometrial cancer, as well as other malignant tumors, and is closely correlated with the clinicopathological features of tumors and the prognosis of patients. Exosome-encapsulated miR-484 shows higher stability in body fluids and serves as a highly promising circulating biomarker. This article systematically reviews the expression characteristics and targeted regulatory mechanisms of miR-484 in cervical cancer, endometrial cancer, and ovarian cancer, as well as its roles and application values in disease diagnosis, prognostic evaluation, and reversal of chemoresistance, aiming to provide a theoretical reference for the translational application of miR-484 in the clinical diagnosis and treatment of gynecologic malignancies.